Shots:

• The P-III COVACTA study will evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) + SOC vs PBO + SOC in adult hospitalized patients with severe COVID-19 pneumonia
• The study is expected to be initiated in early Apr’2020 and will evaluate the therapy in ~300 patients globally- including the US with the 1EPs & 2EPs as clinical status- mortality- mechanical ventilation and ICU variables
• Actemra/RoActemra (IV- SC) is the first approved anti-IL-6 receptor biologic indicated to treat patients with moderate-to-severe active RA. Additionally- Roche received FDA’s EUA for the cobas SARS-CoV-2 Test on Mar 13- 2020- to detect COVID-19

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche